Results 201 to 210 of about 216,339 (397)

Effects of bevacizumab on retinal function in isolated vertebrate retina [PDF]

, 2006
M. Lüke
openalex   +1 more source

The regulatory effects and applications of TIGIT/CD155 on the tumor microenvironment in HCC

VIEW, EarlyView.
Background The interaction between TIGIT and CD155 compromises immune cell efficacy in tumor targeting, potentially driving hepatocellular carcinoma (HCC) progression through diverse molecular pathways. What Was Done This study investigates the interplay between CD155 and TIGIT in regulating CD8+ T cell function and elucidates its implications in HCC ...
Wenting Li, Yukun Li, Yao Li, Mingqi Yang, Haichuan Peng, Hongwei Sun, Ping Jiang, Yizhun Zhu, Qiang Chen, Xiaobing Duan, Wei Zhao   +10 more
wiley   +1 more source

Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia [PDF]

, 2006
Izumi Yamamoto, Adam H. Rogers, Elias Reichel, Paul Yates, Jay S. Duker   +4 more
openalex   +1 more source

Nanotechnology and cell death: Revolutionizing disease treatment with nanoparticle strategies

VIEW, EarlyView.
Traditional disease treatments often face issues such as poor drug targeting and significant side effects, with many complex diseases lacking effective therapies. Our research utilizes tiny nanomaterials to treat diseases by regulating natural cell death processes, improving the immune environment, etc., enabling drugs to act more precisely.
Yiwen Wan, Wangzheqi Zhang, Yan Liao, Chenglong Zhu, Xiaojing Guo, Zui Zou, Mi Li   +6 more
wiley   +1 more source

Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration [PDF]

, 2006
Carsten H. Meyer
openalex   +1 more source

A new clustering: Angiogenesis‐associated molecular classification of lung adenocarcinoma

VIEW, EarlyView.
Lung adenocarcinoma (LUAD) is a heterogeneous disease, with varying patient prognosis and challenges in personalized treatments. We identified three LUAD subtypes based on angiogenesis‐related genes in this study, revealing distinct biological features and key survival‐related genes that could serve as targets for personalized therapies.
Lin Zhu, Li Zhu, Kai Nie, Yuxuan Zhang, Qunhui Chen, Yan Shen, Yifeng Jiang, Lingming Yu, Shaojie Li, Yanbing Sun, Qiming Ni, Jiahui Yu, Guangyu Tao, Jun Xing, John Parrington, Lin Huang, Hong Yu   +16 more
wiley   +1 more source

Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

Clinical Ophthalmology, 2011
Christos I Sinapis1,*, John G Routsias2,*, Angelos I Sinapis1,*, Dimitrios I Sinapis1,*, George D Agrogiannis3, Alkistis Pantopoulou1, Stamatis E Theocharis4, Stefanos Baltatzis5, Efstratios Patsouris3, Despoina Perrea11Laboratory for Experimental ...
Sinapis C, Routsias JG, Sinapis A, Sinapis D, Agrogiannis G, Pantopoulou A, Theocharis SE, Baltatzis S, Patsouris E, Perrea DN   +9 more
doaj  

Intravitreal bevacizumab for peripapillary classic subretinal neovascularization [PDF]

, 2006
Ulrich Spandau, Jost B. Jonas
openalex   +1 more source

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. [PDF]

, 2019
Glioblastoma is the most common primary malignant brain tumor in adults and is associated with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi-institution clinical trial to evaluate immune responses ...
Arrillaga-Romany, Isabel C, Butowski, Nicholas A, Clarke, Jennifer L, Cloughesy, Timothy F, Cohen, Adam L, Colman, Howard, Davidson, Tom B, de Groot, John F, Du, Lin, Ellingson, Benjamin M, Gaffey, Sarah C, Hugo, Willy, Kaley, Thomas J, Kawaguchi, Eric S, Lee, Alexander H, Lee, Eudocia Q, Li, Gang, Liau, Linda M, Mellinghoff, Ingo K, Mochizuki, Aaron Y, Nghiemphu, Phioanh L, O'Brien, Barbara J, Orpilla, Joey R, Prins, Robert M, Reardon, David A, Rytlewski, Julie A, Sanders, Catherine M, Wang, Anthony C, Wen, Patrick Y, Yong, William H   +29 more
core  

Determining the Survival Impact and Cost‐Effectiveness of Multi‐Gene Panel Sequencing in Metastatic Colorectal Cancer With Super Learning Approaches

Health Services Research, EarlyView.
ABSTRACT Objective To determine the effectiveness and cost‐effectiveness of multi‐gene panel sequencing compared to single‐gene KRAS testing for metastatic colorectal cancer (mCRC). Study Setting and Design British Columbia, Canada (BC) is a provincial single‐payer public healthcare system, and it was the first province to publicly reimburse multi‐gene
Emanuel Krebs, Deirdre Weymann, Howard J. Lim, Stephen Yip, Dean A. Regier   +4 more
wiley   +1 more source